| ID | 119038 |
| Author |
Ogawa, H
Yoshinogawa Hospital
Bando, Hiroshi
Yoshinogawa Hospital|Medical Research|Tokushima University|Japan Low Carbohydrate Diet Promotion Association
KAKEN Search Researchers
Abe, T
Yoshinogawa Hospital
Nagahiro, Shinji
Yoshinogawa Hospital|Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Nakanishi, M
Yoshinogawa Hospital
Watanabe, O
Yoshinogawa Hospital
|
| Keywords | Oral semaglutide (Rybelsus)
Type 2 diabetes (T2D)
Gastro Esophageal Reflux Disease (GERD)
Gastrointestinal adverse effects (GIAEs)
Sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC)
|
| Content Type |
Journal Article
|
| Description | Background: Oral semaglutide (Rybelsus) has been recently in focus for type 2 diabetes (T2D).
Case presentation: Case is 61-year-old female with T2D, obesity, fatty liver and Gastro Esophageal Reflux Disease (GERD). Her HbA1c was 13.2% in Dec 2021, and she started to have metformin, empagliflozin and Rybelsus from 3mg to 7mg/day. General situation was improved as -4.2% of HbA1c and -8kg in weight for 4 months. Discussion and Conclusion: This case has GERD, and then the doses of Rybelsus kept 7mg/day. She did not feel any gastrointestinal adverse effects (GIAEs). This impressive case will become reference for diabetic practice. |
| Journal Title |
SunText Review of Medical & Clinical Research
|
| ISSN | 27664813
|
| Publisher | SunText Reviews
|
| Volume | 3
|
| Issue | 3
|
| Start Page | 162
|
| Published Date | 2022-08-19
|
| Rights | This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
|
| DOI (Published Version) | |
| URL ( Publisher's Version ) | |
| FullText File | |
| language |
eng
|
| TextVersion |
Publisher
|
| departments |
Medical Sciences
University Hospital
|
